Goals of Screening Programs. What is Vascular Screening? Assumptions Regarding the Potential Benefits of Screening Programs PAD
|
|
- Lenard Flowers
- 5 years ago
- Views:
Transcription
1 Conflict of Interest Disclosure (Relationships with Industry) An Epidemic of : The Debate Over Population Screening Membership on an advisory board, consultant, or recipient of a research grant from the following companies: Alan T. Hirsch, M.D. Professor of Medicine, Epidemiology & Community Health Director, Vascular Medicine Program, Lillehei Heart Institute University of Minnesota Medical School and School of Public Health Minneapolis, MN Research Grants: Advisory Board: Consulting: Abbott Vascular; Bristol-Myers Squibb/Sanofi-aventis Partnership; Cytokinetics; Viromed AstraZeneca; Merck ev3; Summit Doppler; Pozen Because the evidence is clear that RWI alters conclusions Prevalence of and Cancer in the U.S million Cancer 11 million affects the same number of Americans as cancer and is usually more deadly Sources: Cancer Facts & Figures, American Cancer Society (21); NHLBI Disease and Condition Index-Peripheral Arterial Disease (21) Personal Statement: The bottom line, right up front I do not advocate for vascular screening I do advocate that individuals with an easily detected, fatal, and treatable illness merit achievement of: an accurate, cost-effective diagnosis, linked to prompt access to care, regardless of gender, age, ethnicity, country of origin, or economic status. This is a basic principle of social justice. 1
2 Assumptions Regarding the Potential Benefits of Screening Programs Most arterial diseases are associated with a prolonged asymptomatic phase The first clinical event may be morbid or mortal (fatal or non-fatal MI or stroke) There is therefore a detection gap between the asymptomatic phase and clinically apparent disease. Detection is now feasible Effective treatments exist Pasternak RC et al. JACC 23; 41: Goals of Screening Programs Detection of subclinical vascular disease in populations is feasible (e.g, cimt/carotid duplex, ABI, renal duplex, aortic US); Detection of unrecognized clinical disease is possible in a well-specified target population; Therefore, treatment could be initiated at an earlier phase, preventing morbid events. Additional health goals include: Public education Other societal goals: Promotion of health systems, professional societies, and private business What is Vascular Screening? I Detection Gap I Risk Factor Exposure Subclinical Disease Clinical Disease PARTNERS: Prevalence of and Other CVD in Primary Care Practices 29% of Patients in a Target Population Were Diagnosed With Using An Office-Based ABI Diagnosed Cohort Treated Cohort I Detection Fraction I I- Treatment Fraction -I 29% 44% 56% Creation of a chain of proven efficacy is not easy to establish, prove, disseminate, and maintain in at screening program format. Patients diagnosed with only and CVD 8 ABI=ankle-brachial index; CAD=coronary artery disease; CVD=cardiovascular disease. Hirsch AT et al. JAMA. 21;286:
3 Existing disease Heart Protection Study: Vascular Event by Prior Disease Incidence of events Previous MI Other CHD No prior CHD or CBV disease Diabetes All patients Statin Control Risk vs Control (n=1,269) (n=1,267) Statin favored Placebo % Reduction (P<.1) Reprinted with permission from Heart Protection Study Collaborative Group. Lancet. 22;36:7-22 from Elsevier. 9 % of patients with only Relative Control of Cardiovascular RFs in Patients With only or + CAD Patients with only RF control All RFs controlled In 26: % of patients with +CAD Patients with + CAD 25.2 Risk Factor Control defined as: Systolic BP <14 mmhg, diastolic BP <9 mmhg, glycemia <1.1 g/l, total cholesterol <2. g/l, not smoking for >12 months 51.4 RF controlled All RF controlled Individuals with, c/w CAD, achieve only half of their risk reduction goals. Cacoub et al. Atherosclerosis. 28 Oct 31. [Epub ahead of print] Examples of Current Non-Vascular Health Screening Programs These other disease detection programs were based on a robust evidence Cervical base; cancer The testing strategy Mammography was prospectively evaluated in diverse practice Colorectal settings; screening These programs Prenatal were also detection initially of controversial; common Payor funding congenital for these screening disorders programs (blood, amniotic required establishment fluid, of a ultrasound) societal consensus. Have we reached this level of evidence and consensus? Leg Alert Examples of Vascular Screening Programs Program Sponsor Dates Goals Step Lively A Step Ahead National Council on Aging (SIR) Hoechst Marion Roussel Society for Vascular Nursing detection detection detection MN U of Minnesota detection Legs for Life PARTNERS AVA Society for Interventional Radiology Academic SC; (BMS-Sanofi) Society for Vascular Surgery 1998-present detection, expanded to AAA, CBVD, venous dz detection 21-present Modified from: Hirsch et al. J Vasc Surg 24;39:474-81, AAA, carotid disease 3
4 American Vascular Association National Screening Program CAROTID SCAN -A painless ultrasound test to reduce the risk of stroke The Public (the Market) Has Accepted Vascular Screening Thank you so much for finding my! AORTIC SCAN - To detect aneurysms that could rupture and be fatal Testing - Measurement of circulation to your legs to detect peripheral arterial disease () ABI Ankle:Brachial index Linking Evidence to Practice The Role of Clinical Guidelines (ACC/AHA) Guidelines for the Management of Patients with Peripheral Arterial Disease - 26 TransAtlantic Intersocietal Consensus - 26 United States Preventive Services Task Force (USPSTF) - 25 How Much Evidence Is There To Evaluate Benefit and Harm? Circulation. 28;118: The first two evidence-based consensus statements evaluated the screening question from the perspective of CV risk reduction. The USPSTF did not. 4
5 Defining the At Risk Population for Lower Extremity Age less than 5 years with diabetes, and one additional risk factor (e.g., smoking, dyslipidemia, hypertension, or hyperhomocysteinemia) Age 5 to 69 years and history of smoking or diabetes Age 7 years and older Leg symptoms with exertion (suggestive of claudication) or ischemic rest pain Abnormal lower extremity pulse examination Known atherosclerotic coronary, carotid, or renal artery disease I IIa IIb III Asymptomatic, Ischemic Risk, and the Rationale to Establish the Diagnosis: I I IIa IIb III Individuals with asymptomatic should be screening identified criteria in order and to offer rationale, therapeutic but: interventions known to diminish their increased risk of myocardial Current data infarction, do not permit stroke, and 1A death. recommendations These are strong, consensus-driven, widely accepted IIa IIb III The resting ABI should be used to establish the lower extremity diagnosis in patients with suspected lower extremity, defined as individuals with exertional leg symptoms, with nonhealing wounds, who are 7 years and older or who are 5 years and older with a history of smoking or diabetes. Based on a targeted prevalence of > 2-25% Cost-Effectiveness of Disease Screening: Cost per Life Year Gained Is Lower Extremity Screening Cost-Effective? $1, $8, $6, To $1.3 million Min Max This is almost certainly true, but an evidencebased answer would require both modeling and prospective testing (we are doing this) $4, $2, Pap Smear for Cervical Cancer in Elderly Women *Quality-adjusted life year. TSH for Mild Thyroid Failure* HIV Infection Mammography Occult Fecal for Breast Cancer Blood + Sigmoidoscopy for Colorectal Cancer 5
6 Cost-Effectiveness of Disease Screening: Cost per Death Averted $6, $5, $4, $3, $2, To > $2 million Min Max What is Vascular Screening? Ideally, it is the translation of: (a) cardiovascular epidemiology (use of risk factors and risk markers to identify a vulnerable population); (b) via selection of the highest at risk individuals; (c) to initiate proven treatments, to beneficially improve clinical outcomes Risk Factor Exposure Subclinical Disease Clinical Disease $1, Screening of Newborns for Hemoglobinopathy/ Sickle Cell Colonoscopy/ Sigmoidoscopy for Colorectal Cancer Undiagnosed Cohort Treated Cohort And I believe that this algorithm of evidence-based care should occur in office practice, based on prospective trials, and then be reimbursed. Screening for Vascular Disease: Should Nationwide Programs Be Instituted? Individual societies and hospitals may elect to initiate screening programs for myriad reasons. Private for profit firms may elect to initiate vascular screening programs, to fill a market demand. National scientific organizations and government groups should approach screening based on prospective trials, with proven clinical outcomes, and demonstrated health economic benefit. Thank you 6
Joshua A. Beckman, MD. Brigham and Women s Hospital
Peripheral Vascular Disease: Overview, Peripheral Arterial Obstructive Disease, Carotid Artery Disease, and Renovascular Disease as a Surrogate for Coronary Artery Disease Joshua A. Beckman, MD Brigham
More informationLarry Diaz, MD, FSCAI Mehdi H. Shishehbor, DO, FSCAI
PAD Diagnosis Larry Diaz, MD, FSCAI Metro Health / University of Michigan Health, Wyoming, MI Mehdi H. Shishehbor, DO, FSCAI University Hospitals Harrington Heart & Vascular Institute, Cleveland, OH PAD:
More informationGuidelines for Management of Peripheral Arterial Disease
Guidelines for Management of Peripheral Arterial Disease Subhash Banerjee, MD, FACC, FSCAI Professor of Medicine, Univ. of Texas Southwestern Medical Center Chief, Division of Cardiology, VA North Texas
More informationCLINICAL OUTCOME Vs SURROGATE MARKER
CLINICAL OUTCOME Vs SURROGATE MARKER Statin Real Experience Dr. Mostafa Sherif Senior Medical Manager Pfizer Egypt & Sudan Objective Difference between Clinical outcome and surrogate marker Proper Clinical
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE QUALITY AND OUTCOMES FRAMEWORK (QOF) INDICATOR DEVELOPMENT PROGRAMME Briefing paper QOF indicator area: Peripheral arterial disease Potential output:
More informationISCHEMIC VASCULAR DISEASE (IVD) MEASURES GROUP OVERVIEW
ISCHEMIC VASCULAR DISEASE (IVD) MEASURES GROUP OVERVIEW 2014 PQRS OPTIONS F MEASURES GROUPS: 2014 PQRS MEASURES IN ISCHEMIC VASCULAR DISEASE (IVD) MEASURES GROUP: #204. Ischemic Vascular Disease (IVD):
More information4/7/ The stats on heart disease. + Deaths & Age-Adjusted Death Rates for
+ Update on Lipid Management Stacey Gardiner, MD Assistant Professor Division of Cardiovascular Medicine Medical College of Wisconsin + The stats on heart disease Over the past 10 years for which statistics
More informationManagement of Cardiovascular Disease in Diabetes
Management of Cardiovascular Disease in Diabetes Radha J. Sarma, MBBS, FACP. FACC. FAHA. FASE Professor of Internal Medicine Western University of Health Sciences. Director, Heart and Vascular Center Western
More informationPREVENTION CARE IN ADULTS
PREVENTION CARE IN ADULTS Hong Xiao, M.D. Department of Family & Community Medicine Weight and BMI Abdominal Aortic Aneurysm (AAA) Blood Pressure Breast Exam Breast Cancer Mammogram Breast Cancer BRCA
More informationClinical Practice Guidelines Adult Preventive Health
OERIEW Clinical Practice Guidelines The recommendations detailed in the U.S. Preventive Service Task Force s The Guide to Clinical Services 2010-2011 for Adults are considered medically necessary for the
More informationPrevention of Heart Disease: The New Guidelines
Prevention of Heart Disease: The New Guidelines Nisha I. Parikh MD MPH Assistant Professor of Medicine Division of Cardiology Department of Medicine University of California San Francisco May 18 th 2015
More informationVDF and The Burden of Vascular Disease
VESSEL: The Annual Meeting of the VDF September 23,2012 VDF and The Burden of Vascular Disease David P. Faxon MD President Elect VDF Vice Chair of Medicine Brigham and Women s Hospital Disclosures: Boston
More informationThe Guide to Clinical Preventive Services Recommendations of the U.S. Preventive Services Task Force
The Guide to Clinical Preventive Services 2009 Recommendations of the U.S. Preventive Services Task Force Section 1. Preventive Services Recommended by the USPSTF All recommendation statements in this
More informationDisclosures. Prevention of Heart Disease: The New Guidelines. Summary of Talk. Four guidelines. No relevant disclosures.
Disclosures Prevention of Heart Disease: The New Guidelines No relevant disclosures Nisha I. Parikh MD MPH Assistant Professor of Medicine Division of Cardiology Department of Medicine University of California
More informationSTATINS FOR PAD Long - term prognosis
STATINS FOR PAD Long - term prognosis Prof. Pavel Poredos, MD, PhD Department of Vascular Disease University Medical Centre Ljubljana Slovenia DECLARATION OF CONFLICT OF INTEREST No conflict of interest
More informationEarly Identification of PAD: Evidence to Refute USPSTF Position on Screening
Early Identification of PAD: Evidence to Refute USPSTF Position on Screening Mehdi H. Shishehbor, DO, MPH, PhD Director Endovascular Services Interventional Cardiology & Vascular Medicine Department of
More informationIs there an association between atherosclerosis and chronic venous disease?
Is there an association between atherosclerosis and chronic venous disease? Karel Roztocil, IKEM, Praha Hungarian Society of Angiology and Vascular Surgery Congress, Szombathely 2017 Disclosure Nothing
More informationUSWR 23: Outcome Measure: Non Invasive Arterial Assessment of patients with lower extremity wounds or ulcers for determination of healing potential
USWR 23: Outcome Measure: Non Invasive Arterial Assessment of patients with lower extremity wounds or ulcers for determination of healing potential MEASURE STEWARD: The US Wound Registry [Note: This measure
More informationCarotid Ddisease, Carotid IMT and Risk of Stroke
Carotid Ddisease, Carotid IMT and Risk of Stroke TATJANA RUNDEK, MD PhD Professor of Neurology, Epidemiology and Public Health Director, Clinical translational Division Department of Neurology, Miller
More informationHow would you manage Ms. Gold
How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56
More informationSafety of Anacetrapib in Patients with or
Safety of Anacetrapib in Patients with or at Risk for Coronary Heart Disease Christopher P. Cannon, MD, Sukrut Shah, PhD, RPh, Hayes M. Dansky, MD, Michael Davidson, MD, Eliot A. Brinton, MD, Antonio M.
More informationStatement of Coverage. Preventive Health Services Policy. Policy Specific Section: Preventive Health Guidelines
Statement of Coverage Preventive Health Services Policy Type: Preventive Health Guidelines Policy Specific Section: Medicine Group Plans Effective Date: September 23, 2010 * or upon renewal * Effective
More informationControversies in Cardiac Pharmacology
Controversies in Cardiac Pharmacology Thomas D. Conley, MD FACC FSCAI Disclosures I have no relevant relationships with commercial interests to disclose. 1 Doc, do I really need to take all these medicines?
More informationHeart 101. Objectives. Types of Heart Failure How common is HF? Sign/Symptoms, when to see a doctor? Diagnostic testing
EXAMING HEART FAILURE: HOW TO RECOGNIZE AND TREAT THE WEAK HEART What is Heart Failure? Treatment of Heart Failure End Stage Heart Failure Munir S. Janmohamed M.D. FACC Assistant Clinical Professor of
More informationAbdominal Aortic Aneurysm
Abdominal Aortic Aneurysm David N. Duddleston, MD VP and Medical Director Southern Farm Bureau Life Jackson, Mississippi A Case Ms. Ima Bolgin,, age 54, $1.2 million, sent to you for review. Smoker, ½
More informationThe Changing Landscape of Managing Patients with PAD- Update on the Evidence and Practice of Care in Patients with Peripheral Artery Disease
Interventional Cardiology and Cath Labs The Changing Landscape of Managing Patients with PAD- Update on the Evidence and Practice of Care in Patients with Peripheral Artery Disease Manesh R. Patel MD Chief,
More informationIntroduction. Risk factors of PVD 5/8/2017
PATHOPHYSIOLOGY AND CLINICAL FEATURES OF PERIPHERAL VASCULAR DISEASE Dr. Muhamad Zabidi Ahmad Radiologist and Section Chief, Radiology, Oncology and Nuclear Medicine Section, Advanced Medical and Dental
More information7 th Munich Vascular Conference
7 th Munich Vascular Conference Secondary prevention of major cardiovascular events in patients with CHD or PAD - What can we learn from EUCLID and COMPASS, evaluating Clopidogrel, Ticagrelor and Univ.-Prof.
More informationReview of guidelines for management of dyslipidemia in diabetic patients
2012 international Conference on Diabetes and metabolism (ICDM) Review of guidelines for management of dyslipidemia in diabetic patients Nan Hee Kim, MD, PhD Department of Internal Medicine, Korea University
More informationThe Guidelines Guide: Routine Adult Screening Created March 2009 by Alana Benjamin, MD Last updated: June 29 th, 2010
The Guidelines Guide: Routine Adult Screening Created March 2009 by Alana Benjamin, MD Last updated: June 29 th, 2010 Table of Contents Topic Page Introduction 2 Abbreviations 2 USPSTF Grades of Recommendations
More information1. Which one of the following patients does not need to be screened for hyperlipidemia:
Questions: 1. Which one of the following patients does not need to be screened for hyperlipidemia: a) Diabetes mellitus b) Hypertension c) Family history of premature coronary disease (first degree relatives:
More informationWhen to screen for PAD? Prof. Dr.Tine De Backer Prof. Dr. Jean-Claude Wautrecht
When to screen for PAD? Prof. Dr.Tine De Backer Prof. Dr. Jean-Claude Wautrecht How do we define asymptomatic PAD? A. ABI < 1 B. ABI < 0.9 C. ABI < 0.8 D. ABI > 1 How do we define asymptomatic PAD? A.
More informationCVD risk assessment using risk scores in primary and secondary prevention
CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities
More informationPreventive care guidelines Blue Cross and Blue Shield of Minnesota
Service Recommendation Adult men Adult Children Pregnant abdominal aortic aneurysm One-time screening by ultrasound in men aged 65 to 75 who have ever smoked Screening and counseling to reduce alcohol
More informationTABLE OF CONTENTS. 2. LOWER EXTREMITY PERIPHERAL ARTERIAL DISEASE 2.1. Epidemiology Risk Factors
LOWER EXTREMITY PAD The following is one of three extracted sections lower extremity, renal/mesenteric, and abdominal aortic of the ACC/AHA 2005 Guidelines for the Management of Patients With Peripheral
More informationHYPERTENSION GUIDELINES WHERE ARE WE IN 2014
HYPERTENSION GUIDELINES WHERE ARE WE IN 2014 Donald J. DiPette MD FACP Special Assistant to the Provost for Health Affairs Distinguished Health Sciences Professor University of South Carolina University
More informationManaging HTN in the Elderly: How Low to Go
Managing HTN in the Elderly: How Low to Go Laxmi S. Mehta, MD, FACC The Ohio State University Medical Center Assistant Professor of Clinical Internal Medicine Clinical Director of the Women s Cardiovascular
More informationClinical Policy Title: Abdominal aortic aneurysm screening
Clinical Policy Title: Abdominal aortic aneurysm screening Clinical Policy Number: 08.01.10 Effective Date: August 1, 2017 Initial Review Date: June 22, 2017 Most Recent Review Date: June 5, 2018 Next
More informationUnder the Affordable Care Act (ACA), private insurers except for plans that have been
Brought to you by the insurance professionals at HUB International Preventive Care Once an underused component of the health care world that benefits both employees health and employers health care spending,
More informationClinical Policy Title: Abdominal aortic aneurysm screening
Clinical Policy Title: Abdominal aortic aneurysm screening Clinical Policy Number: 08.01.10 Effective Date: August 1, 2017 Initial Review Date: June 22, 2017 Most Recent Review Date: July 20, 2017 Next
More informationACC NY Cardiovascular Symposium
ACC NY Cardiovascular Symposium Peripheral Vascular Disease: Watch the Heart and the Brain Evolving Role of Exercise, ACE-Inhibitors, Interventional and Surgical Options Mark A. Creager, M.D President,
More informationClinical Policy Title: Abdominal aortic aneurysm screening
Clinical Policy Title: Abdominal aortic aneurysm screening Clinical Policy Number: 08.01.10 Effective Date: August 1, 2017 Initial Review Date: June 22, 2017 Most Recent Review Date: June 5, 2018 Next
More informationCLINICAL PRACTICE EVALUATION I: MEDICAL RECORD REVIEW (Adult Patient Population)
Diplomate: CLINICAL PRACTICE EVALUATION I: MEDICAL RECORD REVIEW (Adult Patient Population) A. RECORD IDENTIFIER INFORMATION 1. Date medical record reviewed (mm/dd/year) / / 2. Patient identifier: 3. Date
More information2013 Cholesterol Guidelines. Anna Broz MSN, RN, CNP, AACC Adult Certified Nurse Practitioner North Ohio Heart, Inc.
2013 Cholesterol Guidelines Anna Broz MSN, RN, CNP, AACC Adult Certified Nurse Practitioner North Ohio Heart, Inc. Disclosures Speaker Gilead Sciences NHLBI Charge to the Expert Panel Evaluate higher quality
More informationNew Guidelines in Dyslipidemia Management
The Third IAS-OSLA Course on Lipid Metabolism and Cardiovascular Risk Muscat, Oman, February 2017 New Guidelines in Dyslipidemia Management Dr. Khalid Al-Waili, MD, FRCPC, DABCL Senior Consultant Medical
More informationTo Do or Not To Do? The Annual Physical- Beyond The PAP And Breast Exam
1/27/2015 To Do or Not To Do? The Annual Physical- Beyond The PAP And Breast Exam Fleur Sack, M.D., FAAFP Society of General Internal Medicine Cochrane review of 182,000 people followed for 9 years : the
More informationPreventive Cardiology Scientific evidence
Preventive Cardiology Scientific evidence Professor David A Wood Garfield Weston Professor of Cardiovascular Medicine International Centre for Circulatory Health Imperial College London Primary prevention
More information2013 ACC/AHA Guidelines on the Assessment of Atherosclerotic Cardiovascular Risk: Overview and Commentary
2013 ACC/AHA Guidelines on the Assessment of Atherosclerotic Cardiovascular Risk: Overview and Commentary The Johns Hopkins Ciccarone Center for the Prevention of Heart Disease Becky McKibben, MPH; Seth
More informationTreatment of Cardiovascular Risk Factors. Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center
Treatment of Cardiovascular Risk Factors Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center Disclosures: None Objectives What do risk factors tell us What to check and when Does treatment
More informationPopulation screening and intervention for vascular disease in Danish men (VIVA): a randomized controlled trial
Population screening and intervention for vascular disease in Danish men (VIVA): a randomized controlled trial Jes S. Lindholt Odense University Hospital Denmark Disclosure Speaker name: Jes Lindholt...
More informationImaging in the Evaluation of Coronary Artery Disease and Abdominal Aortic Aneurysm
Imaging in the Evaluation of Coronary Artery Disease and Abdominal Aortic Aneurysm Mark J. Sands, MD Vice Chairman, Imaging Institute Clinical Operations and Quality Objectives Review of available radiologic
More informationAntiplatelet Therapy in Primary CVD Prevention and Stable Coronary Artery Disease. Καρακώστας Γεώργιος Διευθυντής Καρδιολογικής Κλινικής, Γ.Ν.
Antiplatelet Therapy in Primary CVD Prevention and Stable Coronary Artery Disease Καρακώστας Γεώργιος Διευθυντής Καρδιολογικής Κλινικής, Γ.Ν.Κιλκίς Primary CVD Prevention A co-ordinated set of actions,
More informationDisclosures. TASC, AHA, SVS: What s Happening with the Guidelines? How Are They Relevant? Purpose of Practice Guidelines
TASC, AHA, SVS: What s Happening with the Guidelines? How Are They Relevant? Michael S. Conte MD, FACS Division of Vascular and Endovascular Surgery Co-Director, Heart and Vascular Center UCSF Medical
More informationBest Practices in Cardiac Care: Getting with the Guidelines
Best Practices in Cardiac Care: Getting with the Guidelines December 9, 2014 Agenda Cardiovascular Disease: How do the guidelines fit into an implementation scheme? What the guidelines set out to accomplish
More informationNew Paradigms in Predicting CVD Risk
New Paradigms in Predicting CVD Risk Imaging as an Integrator of Lifetime Risk Exposure Michael J. Blaha MD MPH Presented by: Michael J. Blaha September 24, 2014 1 Talk Outline Risk factors vs. Disease
More information- Lecture - Recommandations ESC : messages importants P. MEYER (Saint Laurent du Var) - Controverse - Qui doit faire l'angioplastie périphérique?
- Lecture - Recommandations ESC : messages importants P. MEYER (Saint Laurent du Var) - Controverse - Qui doit faire l'angioplastie périphérique? Un chirurgien E. DUCASSE (Bordeaux) Un interventionnel
More informationCONTRIBUTING FACTORS FOR STROKE:
CONTRIBUTING FACTORS FOR STROKE: HYPERTENSION AND HYPERCHOLESTEROLEMIA Melissa R. Stephens, MD, FAAFP Associate Professor of Clinical Sciences William Carey University College of Osteopathic Medicine LEARNING
More informationAssessing Cardiovascular Risk to Optimally Stratify Low- and Moderate- Risk Patients. Copyright. Not for Sale or Commercial Distribution
CLINICAL Viewpoint Assessing Cardiovascular Risk to Optimally Stratify Low- and Moderate- Risk Patients Copyright Not for Sale or Commercial Distribution By Ruth McPherson, MD, PhD, FRCPC Unauthorised
More informationUpdate on CVD and Microvascular Complications in T2D
Update on CVD and Microvascular Complications in T2D Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of Miami Miller School of Medicine
More informationMEDICAL POLICY SUBJECT: CORONARY CALCIUM SCORING
MEDICAL POLICY PAGE: 1 OF: 5 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical policy criteria are not applied.
More informationPREVENTIVE HEALTHCARE GUIDELINES INTRODUCTION
PREVENTIVE HEALTHCARE GUIDELINES INTRODUCTION Health Plan of Nevada and Sierra Health and Life suggest that health plan members get certain screening tests, exams and shots to stay healthy. This document
More informationPeripheral Arterial Disease: Objectives. Disclosure. Definition: Peripheral Arterial Disease (PAD)
Geriatric Grand Rounds Tuesday, April 21, 2009 12:00 noon Dr. Bill Black Auditorium Glenrose Rehabilitation Hospital In keeping with Glenrose Rehabilitation Hospital policy, speakers participating in this
More informationOptimal medical therapy in patients with stable CAD
Optimal medical therapy in patients with stable CAD Robert Storey Professor of Cardiology, University of Sheffield and Academic Director and Honorary Consultant Cardiologist, Cardiology and Cardiothoracic
More informationBlood Pressure LIMBO How Low To Go?
Blood Pressure LIMBO How Low To Go? Joseph L. Kummer, MD, FACC Bryan Heart Spring Conference April 21 st, 2018 Hypertension Epidemiology Over a billion people have hypertension Major cause of morbidity
More informationAtherosclerotic Disease Risk Score
Atherosclerotic Disease Risk Score Kavita Sharma, MD, FACC Diplomate, American Board of Clinical Lipidology Director of Prevention, Cardiac Rehabilitation and the Lipid Management Clinics September 16,
More informationNo relevant financial relationships
MANAGEMENT OF LIPID DISORDERS Balancing Benefits and harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial relationships baron@medicine.ucsf.edu
More informationDisclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease
Disclosures Diabetes and Cardiovascular Risk Management Tony Hampton, MD, MBA Medical Director Advocate Aurora Operating System Advocate Aurora Healthcare Downers Grove, IL No conflicts or disclosures
More information9/29/2015. Primary Prevention of Heart Disease: Objectives. Objectives. What works? What doesn t?
Primary Prevention of Heart Disease: What works? What doesn t? Samia Mora, MD, MHS Associate Professor, Harvard Medical School Associate Physician, Brigham and Women s Hospital October 2, 2015 Financial
More informationThe Multiethnic Study of Atherosclerosis (MESA) Cardiovascular Risk in Hispanics
The Multiethnic Study of Atherosclerosis (MESA) Cardiovascular Risk in Hispanics Michael H. Criqui MD, MPH Distinguished Professor and Chief, Division of Preventive Medicine Department of Family and Preventive
More informationContemporary management of Dyslipidemia
Contemporary management of Dyslipidemia Todd Anderson Feb 2018 Disclosure Statement Within the past two years: I have not had an affiliation (financial or otherwise) with a commercial organization that
More informationPreventive Health Guidelines
Preventive Health Guidelines Guide to Clinical Preventive Services Adult LifeWise has adopted the United States Preventive Services Task Force (USPSTF) Guide to Clinical Preventive Services. The guideline
More informationThank you for the opportunity to provide expert advice on the Draft Research Plan on Screening for Peripheral Artery Disease.
January 12, 2012 Robert L. Cosby, Ph.D., MSW Senior Coordinator, USPSTF Department of Health and Human Services Agency for Healthcare Research and Quality Center for Primary Care, Prevention and Clinical
More informationThe Potential Role of Carotid Ultrasound Screening for the prevention of Cardiovascular Disease: A cost-effective addition
The Potential Role of Carotid Ultrasound Screening for the prevention of Cardiovascular Disease: A cost-effective addition By Ann-Marie Chapman, PhD Senior Director, Health Economics & Reimbursement Cardiovascular
More informationHow do we define ethnic healthcare disparities? Ethnic Disparity. Cardiovascular Disease in Asians: Are Asians at Increased Risk?
Cardiovascular Disease in Asians: Are Asians at Increased Risk? November 17, 2007 Gordon L. Fung, MD, MPH, PhD, FACC, FAHA, FACP Director, Asian Heart & Vascular Center Clinical Professor of Medicine UCSF
More informationPAD Characterization Within A Healthcare System" RAPID Face-to-Face Meeting Schuyler Jones, MD September 14, 2016
PAD Characterization Within A Healthcare System" RAPID Face-to-Face Meeting Schuyler, MD September 14, 2016 Interventional Cardiology and Cath Labs Disclosures Research Grants: Agency for Healthcare Research
More informationMapfre Life Insurance Company of Puerto Rico Preventive Services
Service Description Procedure Code Diagnosis Code ICD-9 Diagnosis Code ICD-10 Age/Range Gender Frequency/Limits Effective Date Alcohol misuse counseling clinicians screen adults age 18 years or older for
More informationIschemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010
Ischemic Heart and Cerebrovascular Disease Harold E. Lebovitz, MD, FACE Kathmandu November 2010 Relationships Between Diabetes and Ischemic Heart Disease Risk of Cardiovascular Disease in Different Categories
More informationLessons from Recent Atherosclerosis Trials
Lessons from Recent Atherosclerosis Trials Han, Ki Hoon MD PhD Asan Medical Center Seoul, Korea Change of concept Primary vs. secondary prevention Low risk vs. High risk High Risk CHD and equivalents CHD
More informationSupplement materials:
Supplement materials: Table S1: ICD-9 codes used to define prevalent comorbid conditions and incident conditions Comorbid condition ICD-9 code Hypertension 401-405 Diabetes mellitus 250.x Myocardial infarction
More informationRikshospitalet, University of Oslo
Rikshospitalet, University of Oslo Preventing heart failure by preventing coronary artery disease progression European Society of Cardiology Dyslipidemia 29.08.2010 Objectives The trends in cardiovascular
More informationPlacebo-Controlled Statin Trials EXPLAINING THE DECREASE IN DEATHS FROM CHD! PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN EXPLAINING THE DECREASE IN
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING THE DECREASE
More informationMedical management of abdominal aortic aneurysms
Medical management of abdominal aortic aneurysms Definition of AAA - Generally a 50% increase in native vessel diameter - Diameter 3 cm - Relative measures compared with nondiseased aortic segments less
More informationInflammation as A Target for Therapy. Focus on Residual Inflammatory Risk
ESC Rome Monday August 29, 2016 Inflammation as A Target for Therapy Focus on Residual Inflammatory Risk Paul M Ridker, MD Eugene Braunwald Professor of Medicine Harvard Medical School Director, Center
More informationMichigan Department of Health and Human Services Preventive Services Coverage Guidelines Healthy Michigan Plan
Plan The Patient Protection and Affordable Care Act have designated specific resources that identify the services required for coverage by the act. The following lists of services, CPT, and HCPCS codes
More informationDapagliflozin and Outcomes in Patients with Peripheral Artery Disease: Insights from DECLARE-TIMI 58
Dapagliflozin and Outcomes in Patients with Peripheral Artery Disease: Insights from DECLARE-TIMI 58 Marc P. Bonaca MD MPH for the DECLARE TIMI 58 Investigators American College of Cardiology March 2019
More informationPeripheral Arterial Disease Medical Approach and Management
Peripheral Arterial Disease Medical Approach and Management April 2, 2016 Michael F. Hagerty, MD FACC PAD: Classic and New Concepts Let s take a look at what s new and what s old or classic in 2016. PAD:
More informationLipid Management: The Next Level How Will the New ACC/AHA Guidelines Change My Practice
Lipid Management: The Next Level How Will the New ACC/AHA Guidelines Change My Practice Vera Bittner, MD, MSPH Professor of Medicine Section Head, Preventive Cardiology Medical Director, Cardiac Rehabilitation
More informationHypertension. Does it Matter What Medications We Use? Nishant K. Sekaran, M.D. M.Sc. Intermountain Heart Institute
Hypertension Does it Matter What Medications We Use? Nishant K. Sekaran, M.D. M.Sc. Intermountain Heart Institute Hypertension 2017 Classification BP Category Systolic Diastolic Normal 120 and 80 Elevated
More informationVascular disease. Structural evaluation of vascular disease. Goo-Yeong Cho, MD, PhD Seoul National University Bundang Hospital
Vascular disease. Structural evaluation of vascular disease Goo-Yeong Cho, MD, PhD Seoul National University Bundang Hospital resistance vessels : arteries
More informationWhich CVS risk reduction strategy fits better to carotid US findings?
Which CVS risk reduction strategy fits better to carotid US findings? Dougalis A, Soulaidopoulos S, Cholongitas E, Chalevas P, Vettas Ch, Doumtsis P, Vaitsi K, Diavasti M, Mandala E, Garyfallos A 4th Department
More informationTHE ESC/EAS LIPID GUIDELINES IN THE ELDERLY
THE ESC/EAS LIPID GUIDELINES IN THE ELDERLY Alberico L. Catapano alberico.catapano@unimi.it Alberico L. Catapano Potential Conflict Of Interest Prof. Catapano has received honoraria, lecture fees, or research
More informationJohn J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam
Latest Insights from the JUPITER Study John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Inflammation, hscrp, and Vascular Prevention
More informationDyslipidemia in the light of Current Guidelines - Do we change our Practice?
Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dato Dr. David Chew Soon Ping Senior Consultant Cardiologist Institut Jantung Negara Atherosclerotic Cardiovascular Disease
More informationFamilial hypercholesterolaemia in children and adolescents
Familial hypercholesterolaemia in children and adolescents Rationale and recommendations for early identification and treatment European Atherosclerosis Society Consensus Panel Slide deck adapted from:
More informationIntroduction. Objective. Critical Questions Addressed
Introduction Objective To provide a strong evidence-based foundation for the treatment of cholesterol for the primary and secondary prevention of ASCVD in women and men Critical Questions Addressed CQ1:
More informationWhy Prevention? Why is Prevention Difficult? Overview of Preventive Medicine for Family Physicians. Levels of Prevention
Overview of Preventive Medicine for Family Physicians Larry Dickey, MD, MPH Medical Director, Office of Health Information Technology, California Department of Health Care Services Associate Adjunct Professor,
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE QUALITY AND OUTCOMES FRAMEWORK (QOF) INDICATOR DEVELOPMENT PROGRAMME Briefing paper QOF indicator area: Primary prevention of CVD Potential output:
More informationNew Guidelines in Dyslipidemia Management
The Fourth IAS-OSLA Course on Lipid Metabolism and Cardiovascular Risk Muscat, Oman, February 2018 New Guidelines in Dyslipidemia Management Dr. Khalid Al-Waili, MD, FRCPC, DABCL Senior Consultant Medical
More informationWhy Prevention? Why is Prevention Difficult? Overview of Preventive Medicine for Family Physicians. Levels of Prevention
Overview of Preventive Medicine for Family Physicians Larry Dickey, MD, MPH Medical Director, Office of Health Information Technology, California Department of Health Care Services Associate Adjunct Professor,
More informationTreating Heart Failure in Biodiverse Patient Populations: Best Practices and Unveiling Disparities in Blacks
Treating Heart Failure in Biodiverse Patient Populations: Best Practices and Unveiling Disparities in Blacks 12th Annual Leadership Summit on Health Disparities & Congressional Black Caucus Spring Health
More information